19th Nov 2008 07:00
19 NOVEMBER 2008
HENDERSON MORLEY PLC
(AIM: HML)
AGM STATEMENT
The Board of Henderson Morley plc ("Henderson Morley" or "the Company"), the AIM quoted biotechnology company, announces that Chairman, Andrew Knight will make the following comments at today's AGM being held at 1200 noon.
"As it is less than a month since the release of our final results, I do not intend to make a lengthy AGM statement.
"Significant interest in our Feline Herpes Virus treatment has meant that we have now entered into discussions with 5 potential partners which may lead to the Company considering an early licence before completion of the trial which is currently ongoing. The Board will keep shareholders informed of progress of these discussions.
"I would also like to confirm that, in respect of our Koi Herpes Virus vaccine trial, we are still on track to deliver news on this trial before the end of the calendar year."
---ENDS---
ENQUIRIES:
HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome
BREWIN DOLPHIN INVESTMENT BANKING 0113 241 0126
Neil Baldwin
HYBRIDAN LLP 0203 159 5085
Claire Noyce/Stephen Austin
Further information on Henderson Morley plc can be accessed through the Company's website at www.henderson-morley.com
Notes to Editors:
Henderson Morley was founded in 1996 with the objective of developing its anti viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform and has been developed in-house and HML wholly owns the patent IPR.
Related Shares:
HML.L